Press Release : Roche's faricimab meets primary -2-

   Founded in 1896, Roche continues to search for better ways to prevent, 
diagnose and treat diseases and make a sustainable contribution to 
society. The company also aims to improve patient access to medical 
innovations by working with all relevant stakeholders. More than thirty 
medicines developed by Roche are included in the World Health 
Organization Model Lists of Essential Medicines, among them life-saving 
antibiotics, antimalarials and cancer medicines. Moreover, for the 
twelfth consecutive year, Roche has been recognised as one of the most 
sustainable companies in the Pharmaceuticals Industry by the Dow Jones 
Sustainability Indices (DJSI). 
 
 
 
   The Roche Group, headquartered in Basel, Switzerland, is active in over 
100 countries and in 2019 employed about 98,000 people worldwide. In 
2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 
61.5 billion. Genentech, in the United States, is a wholly owned member 
of the Roche Group. Roche is the majority shareholder in Chugai 
Pharmaceutical, Japan. For more information, please visit 
https://www.globenewswire.com/Tracker?data=86Xaa-DOLeQHQUi4_K7RObWTNtXydpqPlTcrUvBq99Yh5lu6IfhtvTFLtzi3UZ7mRIXrBiet1NCCwr1a4E88LA== 
www.roche.com. 
 
 
 
   All trademarks used or mentioned in this release are protected by law. 
 
 
 
   References 
 
   [1] Bright Focus Foundation. Age-Related Macular Degeneration: Facts & 
Figures. [Internet; cited December 2020]. Available from: 
https://www.brightfocus.org/macular/article/age-related-macular-facts-figures. 
 
 
   [2] Connolly E, et al. Prevalence of age-related macular degeneration 
associated genetic risk factors and 4-year progression data in the Irish 
population. Br J Ophthalmol. 2018;102:1691-95. 
 
   [3] Wong WL ,et al. Global prevalence of age-related macular 
degeneration and disease burden projection for 2020 and 2040: a 
systematic review and meta-analysis. The Lancet Global Health. 
2014;2:106-16 
 
   [4] Heier JS, et al. The Angiopoietin/Tie pathway in retinal vascular 
diseases: a review. Retina-J Ret Vit Dis. 2021;41:1-19. 
 
   [5] Holz FG, et al. Multi-country real-life experience of anti-vascular 
endothelial growth factor therapy for wet age-related macular 
degeneration. Br J Ophthalmol. 2015;99:220-6. 
 
   [6] Schmidt-Erfurth U, et al. Intravitreal aflibercept injection for 
neovascular age-related macular degeneration: ninety-six-week results of 
the VIEW studies. Ophthalmology. 2014;121:193-201. 
 
   [7] FDA. Highlights of prescribing information, Macugen, 2011 [Internet; 
cited 2020 December]. Available 
from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021756s018lbl.pdf. 
 
 
   [8] Khan M, et al. Targeting Angiopoietin in retinal vascular diseases: 
A literature review and summary of clinical trials involving faricimab. 
Cells. 2020;9:1869. 
 
   [9] Yau JWY, et al. Global prevalence and major risk factors of diabetic 
retinopathy. Diabetes Care. 2012;35:556-64. 
 
   [10] Clinical Trials.gov. A study to evaluate the efficacy and safety of 
faricimab in participants with neovascular age-related macular 
degeneration (TENAYA) [Internet; cited 2020 December]. Available from: 
https://clinicaltrials.gov/ct2/show/NCT03823287. 
 
   [11] Clinical Trials.gov. A study to evaluate the efficacy and safety of 
faricimab in participants with neovascular age-related macular 
degeneration (LUCERNE) [Internet; cited 2020 December]. Available from: 
https://clinicaltrials.gov/ct2/show/NCT03823300. 
 
   [12] Pennington KL, DeAngelis MM. Epidemiology of age-related macular 
degeneration (AMD): associations with cardiovascular disease phenotypes 
and lipid factors. Eye and Vision. 2016;3:34. 
 
   [13] Little K., et al. Myofibroblasts in macular fibrosis secondary to 
neovascular age-related macular degeneration-the potential sources and 
molecular cues for their recruitment and activation. EBioMedicine. 
2018;38:283-91. 
 
   [14] Campochiaro, P, et al. Primary analysis results of the phase 3 
archway trial of the port delivery system with ranibizumab for patients 
with neovascular AMD. American Society of Retina Specialists Annual 
Meeting; 2020 Jul 24-26. 
 
 
 
   Roche Group Media Relations 
 
   Phone: [phone] / e-mail: 
https://www.globenewswire.com/Tracker?data=OwpkIVV32jf0kOkOf1TVeYKPev4Z6DRsUMGkinJ0hCjvCphed7NdH40afwKg2GUijkAsnKQiZ8NchcI4mCttksm5XvylBDCNk03INyZmY_5qah_IbTGwjfWNIPdbcz1F 
[e-mail] 
 
 
 
 
 
 
 
 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: [phone]     Phone: [phone] 
Dr. Daniel Grotzky          Karsten Kleine 
 Phone: [phone]     Phone: [phone] 
Nina Mählitz           Nathalie Meetz 
 Phone: [phone]     Phone: [phone] 
Dr. Barbara von Schnurbein 
 Phone: [phone] 
 
 
 
 
 
 
 
 
Roche Investor Relations 
Dr. Karl Mahler                               Jon Kaspar Bayard 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]          e-mail: mailto:[e-mail] 
 [e-mail]                         [e-mail] 
--------------------------------------------  ------------------------------------------- 
Dr. Sabine Borngräber                    Dr. Bruno Eschli 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]   e-mail: mailto:[e-mail] 
 [e-mail]                  [e-mail] 
--------------------------------------------  ------------------------------------------- 
Dr. Birgit Masjost                            Dr. Gerard Tobin 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]       e-mail: mailto:[e-mail] 
 [e-mail]                      [e-mail] 
--------------------------------------------  ------------------------------------------- 
 
Investor Relations North America 
Loren Kalm                                    Dr. Lisa Tuomi 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]            e-mail: mailto:[e-mail] 
 [e-mail]                           [e-mail] 
--------------------------------------------  ------------------------------------------- 
 
 
 
 
   Attachment 
 
 
   -- 25012021_MR_ Faricimab nAMD_ EN 
      https://ml-eu.globenewswire.com/Resource/Download/f1f9a8bb-ea5c-4aac-847c-3929e3bd3a1f

(END) Dow Jones Newswires

January 25, 2021 01:00 ET (06:00 GMT)